Pupillometry and Somatosensory Evoked Potential in Cardiac Arrest (PASCA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04720482 |
Recruitment Status :
Recruiting
First Posted : January 22, 2021
Last Update Posted : January 26, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Cardiac Arrest Cardiopulmonary Arrest With Successful Resuscitation Resuscitation | Diagnostic Test: Somatosensory Evoked Potentials Diagnostic Test: Automated Pupillometry |
Background:
Anoxic/ischemic brain injury is the most common cause of death among comatose survivors of cardiac arrest (CA). The neurological prognosis of these patients is assessed using the multimodal prognostication model, which includes several methods. Somatosensory Evoked Potentials (SSEP) and Pupillary Light Reflex (PLR) are key methods for prognostication, as both have low false positive rates. Though they assess different functions of the brain, they should both be sensitive to severe anoxic/ischemic injury from cardiac arrest. The primary aim of the study is to describe the association between PLR quantified as the Neurological Pupil index (NPi) and bilateral absence of the cortical SSEP signal in patients remaining comatose after cardiac arrest. The secondary aim is to define a NPi cut-off value that renders a false positive rate (FPR) of less than 5% for a bilaterally absent SSEP response.
Methods:
An explorative, prospective, observational, cohort of 50 adult (>18 years) comatose survivors of CA admitted to the intensive care unit at Sahlgrenska University Hospital. The results from routine SSEP performed > 48 hours after CA and PLR assessed using NPi calculated by automated pupillometry are compared. Neurological outcome at hospital discharge is classified using the modified Rankin Scale (mRS), where poor neurological outcome is defined by mRS 4-6.
Statistical analysis:
In order to find a significant difference in NPi of 0.7 with a power of 95% with two-sided Fisher's non-parametric permutation test, 45 patients are needed assuming allocation 2:1 and unequal SD in the groups 0.37 and 0.67, calculated from the IQR above, and significance level 0.01. To account for uncertainty within these estimates, we aim to include 50 patients with a complete protocol.
A receiver operating characteristics curve (ROC-curve) will be used to find the NPi cut-off values resulting in a false positive rate of less than 5% for absent SSEP to predict poor neurological outcome. NPi values below the cut-off i.e., values consistent with poor outcome, will be used to calculate the predictive value for SSEP at its given prevalence. Fisher's exact test will be used to assess correlation between NPi and SSEP.
Discussion:
A clear correlation between the absence of cortical SSEP response and NPi values will permit application of the adequate method to the individual patient. This may also enable rationalisation of the multimodal assessment of the neurological prognosistication using a smaller number of methods. In clinical practice, this may render the prognostication of neurological function of comatose patients after cardiac arrest more accurate, as well as more cost- and time efficient.
Study Type : | Observational |
Estimated Enrollment : | 50 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | The Capacity of Neurological Pupil Index to Predict the Absence of Somatosensory Evoked Potentials in Comatose Survivors of Cardiac Arrest |
Actual Study Start Date : | February 3, 2020 |
Estimated Primary Completion Date : | June 30, 2022 |
Estimated Study Completion Date : | June 30, 2022 |

Group/Cohort | Intervention/treatment |
---|---|
Comatose survivors of cardiac arrest
Adult (>18 years) patients remaining comatose during intensive care 48 hours after cardiac arrest. All patients are submitted to both clinical routine measurements: pupillometry and somatosensory evoked potentials.
|
Diagnostic Test: Somatosensory Evoked Potentials
SSEP performed bilaterally with stimulation of the median nerve
Other Name: Cortical N20 response Diagnostic Test: Automated Pupillometry PLR quantified as NPi using a handheld automated pupillometer
Other Name: Neurological Pulpil index |
- The association between NPi and bilateral absence of the cortical SSEP response. [ Time Frame: SSEP and pupillometry performed 48 hours after cardiac arrest ]ROC curve analysis
- NPi cut-off value that renders a false positive rate (FPR) of less than 5% for a bilaterally absent SSEP response. [ Time Frame: SSEP and pupillometry performed 48 hours after cardiac arrest ]Analysed by stepwise crosstabulation of NPi values against absent cortical SSEP response.
- Predictive capacity for SSEP and NPi for death at 30 days and neurological outcome at hospital discharge [ Time Frame: Assessed from medical records within a month after cardiac arrest ]Analysed as sensitivity, specificity and odds ratio

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
>18-year-old comatose survivors of cardiac arrest with Glasgow coma scale < 9.
Exclusion Criteria:
return of consciousness before SSEP is performed; pregnancy; intracranial bleeding; traumatic brain injury; palliative care and lack of next of kin.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04720482
Contact: Christian CA Rylander, MD, PhD | +46313421096 | christian.rylander@vgregion.se | |
Contact: Meena K Thuccani, Med. Lic | +46709282625 | meena.thuccani@vgregion.se |
Sweden | |
avd 96 CIVA Sahlgrenska University Hospital | Recruiting |
Göteborg, Sweden, 413 45 | |
Contact: Christian Rylander, MD, PhD +46 31 342 10 00 | |
Principal Investigator: Christian Rylander, MD, PhD |
Responsible Party: | Christian Rylander, Associate Professor, Sahlgrenska University Hospital, Sweden |
ClinicalTrials.gov Identifier: | NCT04720482 |
Other Study ID Numbers: |
PASCA |
First Posted: | January 22, 2021 Key Record Dates |
Last Update Posted: | January 26, 2021 |
Last Verified: | January 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Heart Arrest Heart Diseases Cardiovascular Diseases |